Related Experiment Videos
Advanced epithelial ovarian cancer: 1998 consensus statements.
J S Berek1, K Bertelsen, A du Bois
1Department of Internal Medicine, Utrecht University Hospital, The Netherlands.
Summary
For advanced ovarian cancer, cisplatin plus paclitaxel is superior to older treatments. Carboplatin plus paclitaxel offers a less toxic, convenient alternative, justifying its widespread use.
Area of Science:
- Oncology
- Gynecologic Oncology
Background:
- Consensus reached by ovarian cancer specialists in 1998.
- Addressed standard practice and research for advanced epithelial ovarian cancer.
Purpose of the Study:
- To establish consensus on key issues in advanced ovarian cancer management.
- To guide current therapy and future research directions.
Main Methods:
- Expert groups convened to discuss prognostic factors, treatment options (surgery, chemotherapy), and investigational drugs.
- Issues addressed included identifying non-responders, optimal current therapy, and research priorities.
Main Results:
- Cisplatin plus paclitaxel demonstrated superiority over cisplatin plus cyclophosphamide for untreated advanced ovarian cancer (Level I evidence).
- Carboplatin plus paclitaxel is a viable, less toxic alternative, supporting its broader adoption.
- A minority recommended continued cisplatin plus paclitaxel for select patients pending survival data.
Conclusions:
- Treatment guidelines for advanced ovarian cancer were updated based on expert consensus.
- Proposed new endpoints and a Trials Network for future clinical research in ovarian cancer.